Clinical Trials
Search our team at AdventHealth Research Institute
-
Prospective Evaluation of the Clinical Utility of Peroral Endoscopic Myotomy for Gastrointestinal Motility Disorders.
This study is currently enrolling.Associated Conditions: Interventional EndoscopyResearch Area: Digestive Health and SurgeryResearch Location: OrlandoThird space endoscopy, commonly referred as submucosal endoscopy, is founded on the principle that the deeper layers of the gastrointestinal (GI) tract can be accessed by tunneling in the submucosal...
-
NCT06951490
Evaluating the Predictive Value of a Negative PillSense Result for Safe Discharge in Hospitalized Patients with Positive Hemoccult Tests and/or Anemia Without Overt Gastrointestinal Bleeding.
This study is currently enrolling.Associated Conditions: GI / HepatologyResearch Area: Digestive Health and SurgeryResearch Location: OrlandoThis research is being conducted to address the challenges associated with the current diagnostic approach for hospitalized patients with anemia, and/or positive stool-based study for occult...
-
NCT06459869
A multicentre, open label, non-randomized, phase 1b trial of NG-350A, a tumourselective anti-CD40-expressing adenoviral vector, in combination with chemoradiotherapy in locally advanced rectal cancer (FORTRESS)
This study is currently enrolling.Associated Conditions: GastrointestinalResearch Area: Clinical Cancer ResearchResearch Location: OrlandoThe purpose of this research is to test an investigational drug called NG-350A as a possible treatment for locally advanced rectal cancer (LARC). An investigational drug is one that has not been...
-
A Randomized, Open-label Phase 3 Study of Amivantamab + mFOLFOX6 or FOLFIRI Versus Cetuximab + mFOLFOX6 or FOLFIRI as First-line Treatment in Participants with RAS/RAF Wild-Type Unresectable or Metastatic Left-sided Colorectal Cancer (OrigAMI-2)
This study is currently enrolling.Associated Conditions: GastrointestinalResearch Area: Clinical Cancer ResearchResearch Location: AltamonteThe purpose of this study is to compare the effects of two anticancer drugs (amivantamab and cetuximab) when each is given in combination with standard colorectal cancer (CRC) chemotherapies. to...
-
NCT06750094
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy
This study is currently enrolling.Associated Conditions: GastrointestinalResearch Area: Clinical Cancer ResearchResearch Location: OrlandoThe purpose of this study is to compare the effects of amivantamab in combination with standard of care chemotherapy (FOLFIRI) against cetuximab or bevacizumab in combination with FOLFIRI in...
-
NCT06614192
An Open Label, Randomized, Controlled, Global Phase 3 Study Comparing ABBV-400 Monotherapy to LONSURF (Trifluridine and Tipiracil) plus Bevacizumab in Subjects with c-Met Over-Expressed Refractory Metastatic Colorectal Cancer (AndroMETa-CRC-064)
This study is currently enrolling.Associated Conditions: GastrointestinalResearch Area: Clinical Cancer ResearchResearch Location: OrlandoThe purpose of this study is to determine the recommended ABBV-400 dose when ABBV-400 is given alone (monotherapy) in Stage 1, and to assess if ABBV-400 monotherapy is a safe and effective treatment...
-
NCT06109779
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination with Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer with Curative Intent (ARTEMIDE-Biliary01)
This study is currently enrolling.Associated Conditions: GastrointestinalResearch Area: Clinical Cancer ResearchResearch Location: OrlandoThe purpose of this research is to understand if the study drug rilvegostomig (together with chemotherapy) can help to reduce the risk of biliary tract cancer coming back after surgery. We will...
-
NCT06203600
Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS ? 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
This study is currently enrolling.Associated Conditions: GastrointestinalResearch Area: Clinical Cancer ResearchResearch Location: OrlandoThis study is being done to answer the following questions: Can adding a drug to the usual treatment for advanced stomach and esophageal cancers make it less likely that these cancers will grow or...
-
NCT06006923
Randomized trial of Regorafenib in Combination with Pembrolizumab or Pembrolizumab Monotherapy for Patients with MSI-H Colorectal Cancer
This study is currently enrolling.Associated Conditions: GastrointestinalResearch Area: Clinical Cancer ResearchResearch Location: OrlandoThis is a research study to find out if researchers can lower the chance of your colorectal cancer growing or spreading by using a combination of regorafenib and pembrolizumab compared to...
-
NCT05677490
Randomized Phase III Trial of mFOLFIRINOX +/- Nivolumab vs. FOLFOX +/- Nivolumab for First-Line Treatment of Metastatic HER2-Negative Gastroesophageal Adenocarcinoma
This study is currently enrolling.Associated Conditions: GastrointestinalResearch Area: Clinical Cancer ResearchResearch Location: Porter, ColoradoThe purpose of this study is to compare the usual treatment alone to adding a third chemotherapy drug called irinotecan to the usual treatment. The addition of irinotecan to the usual treatment could...
-
NCT06346392
D9802C00001 (CLARITY GC01): A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared with Investigator’s Choice of Therapy in Second- or Later-Line Adult Participants with Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
This study is currently enrolling.Associated Conditions: GastrointestinalResearch Area: Clinical Cancer ResearchResearch Location: OrlandoWe are doing this study to learn more about: the effectiveness and safety of the investigational study drug AZD0901 compared to a standard therapy that will be selected by your study doctor per your...
-
NCT04579224
A Phase III Randomized Trial of Eribulin (NSC #707389) with Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy
This study is currently enrolling.Associated Conditions: GastrointestinalResearch Area: Clinical Cancer ResearchResearch Location: Porter, Colorado